Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Rosuvastatin and Dabigatran with Nurandociguat in Healthy Participants
NCT07515339Phase 1Withdrawn
- Sponsor
- Bayer
- Start
- Apr 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAY3283142 in chronic kidney disease (CKD) (2 arms), sponsored by Bayer. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve. Planned start Apr 2026; status: withdrawn.
02
Drugs
BAY3283142
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07515339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07515339.